Skip to main content
Figure 3 | Journal of Neuroinflammation

Figure 3

From: Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice

Figure 3

Functional assessment of mAb 1379 on alternative complement pathway activity after traumatic brain injury (TBI). Relative alternative pathway complement activity levels (normalized to 100%) were determined by zymosan assay in murine serum samples, as described in the methods section. The mAb 1379-injected mice showed a significant decrease in alternative complement activity compared to placebo-injected mice at 4 hours and 24 hours, but not at 7 days after TBI. Data are shown as mean levels ± SD of n = 5 animals per group and time-point. *P < 0.05, for TBI_mAb 1379 (4 h) and TBI_mAb 1379 (24 h) vs. TBI_placebo and sham; unpaired Student's t-test.

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094